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ABSTRACT
Objective Evaluate ustekinumab, an anti-interleukin
(IL)-12 and IL-23 antibody, effects on radiographic
progression in psoriatic arthritis (PsA).
Methods We conducted preplanned integrated analyses
of combined radiographic data from PSUMMIT-1 and
PSUMMIT-2 phase 3, randomised, controlled trials.
Patients had active PsA despite prior conventional and/or
biologic disease-modifying antirheumatic drugs (≥5/66
swollen, ≥5/68 tender joints, C-reactive protein
≥3.0 mg/L, documented plaque psoriasis). Patients
(PSUMMIT-1, n=615; PSUMMIT-2, n=312) were
randomised to ustekinumab 45 mg, 90 mg, or placebo, at
weeks (wk) 0, 4 and every (q) 12 wks. At wk 16, patients
with <5% improvement in tender/swollen joint counts
entered blinded early escape. All other placebo patients
received ustekinumab 45 mg at wk 24 and wk 28, then
q 12 wks. Radiographs of hands/feet at wks 0/24/52
were assessed using PsA-modiﬁed van der Heijde-Sharp
(vdH-S) scores; combined PSUMMIT-1 and PSUMMIT-2
changes in total vdH-S scores from wk 0 to wk 24
comprised the prespeciﬁed primary radiographic analysis.
Treatment effects were assessed using analysis of variance
on van der Waerden normal scores (factors=treatment,
baseline methotrexate usage, and study).
Results Integrated data analysis results indicated that
ustekinumab-treated patients (regardless of dose)
demonstrated signiﬁcantly less radiographic progression
at wk 24 than did placebo recipients (wk 0–24 total
vdH-S score mean changes: 0.4-combined/individual
ustekinumab dose groups, 1.0-placebo; all p<0.02). From
wk 24 to wk 52, inhibition of radiographic progression
was maintained for ustekinumab-treated patients, and
progression was substantially reduced among initial
placebo recipients who started ustekinumab at wk 16 or
wk 24 (wk 24 – wk 52, total vdH-S score mean change:
0.08).
Conclusions Ustekinumab 45 and 90 mg treatments
signiﬁcantly inhibited radiographic progression of joint
damage in patients with active PsA.
INTRODUCTION
Psoriatic arthritis (PsA) is an inﬂammatory arthro-
pathy occurring in association with skin psoriasis.
The PsA musculoskeletal presentation is heteroge-
neous, involving peripheral joints, entheses, other
periarticular tissues, and/or axial spine. The PsA
radiographic spectrum is highly variable and
includes patients with mild, non-destructive joint
inﬂammation and those with severe, debilitating
joint pain and deformities resulting from progres-
sive joint damage. Diverse radiographic ﬁndings are
reported to include erosions and joint space nar-
rowing, soft tissue changes, and new bone forma-
tion including juxta-articular periosteal reaction
and ankylosis.1 2 Recent data implicate T helper
(Th)-17 cells, key effectors in inﬂammation and
tissue damage in several immune-mediated diseases,
as playing a role in the immunopathophysiology of
PsA.3 This cytokine axis can be targeted via inhibit-
ing blockade of IL-23, which is required for Th17
cell development, or blocking the activity of the
primary cytokine produced by these cells, IL-17.
Reﬂecting the considerable unmet clinical need,
several novel therapeutics have been explored in
PsA. One agent, ustekinumab (Stelara, Janssen
Biotech Inc, Horsham, Pennsylvania, USA), is a
human immunoglobulin G1κ monoclonal antibody
that binds to the common p40-subunit shared by
IL-12 and IL-23. Ustekinumab is approved for treat-
ing moderate to severe psoriasis, as established in
large phase three trials.4–6 Ustekinumab also demon-
strated efﬁcacy in patients with active PsA in a phase
two trial7 and in the larger, phase 3 PSUMMIT-18
and PSUMMIT-29 trials, and has recently gained
approval in this indication in the USA and the EU.
PSUMMIT-1 included only patients naive to bio-
logic antitumour necrosis factor-α (anti-TNF) treat-
ments, whereas PSUMMIT-2 enrolled patients naive
to and previously treated with biologic anti-TNF
agents. Change in radiographic progression from
baseline at wk 24 using data combined from the two
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studies, assessed via PsA-modiﬁed van der Heijde-Sharp (vdH-S)
scores, was a prespeciﬁed major secondary study endpoint for
both studies. This approach was taken because of the similar trial
designs and contemporaneous enrolment and reading of radio-
graphs adopted in the programme, and because the initial power
calculation indicated the need for a sample size larger than would
be available from either study individually to detect a signiﬁcant
treatment effect (also see online supplementary text). These inte-
grated radiographic analyses through 1 year of ustekinumab treat-
ment in the combined phase 3 PSUMMIT-1 and PSUMMIT-2
trials are reported herein.
METHODS
Patients and trial designs
Patient inclusion criteria and trial designs, which were similar
across the PSUMMIT-18 and PSUMMIT-29 trials, have been
detailed. Brieﬂy, adult patients with active PsA for ≥6 months,
despite ≥3 months of disease-modifying antirheumatic agents
and/or ≥4 wks of non-steroidal anti-inﬂammatory agents were
eligible. In PSUMMIT-2, 150 to 180 of the 300 planned rando-
mised patients were required to have been previously treated,
without consideration of reasons why therapy was discontinued,
with biologic anti-TNF agents for at least 8 (etanercept, adali-
mumab, golimumab, certolizumab) or 14 (inﬂiximab) wks at
typical doses. However, entry with less exposure was permitted
if there was documented intolerance to a TNF-inhibitor. For
both PSUMMIT-1 and PSUMMIT-2, active PsA was deﬁned by
the presence of ≥5/66 swollen and ≥5/68 tender joints at
screening and baseline, a serum C-reactive protein level
≥6.0 mg/L (modiﬁed to ≥3.0 mg/L after study start; upper limit
of normal 10 mg/L) at screening, and active or a documented
history of plaque psoriasis.
The PSUMMIT-1 (NCT01009086, EudraCT 2009-012264-
14) and PSUMMIT-2 (NCT01077362, EudraCT 2009-012265-
60) studies were conducted according to the Declaration of
Helsinki and International Committee on Harmonisation good
clinical practices. The protocols were reviewed and approved by
each site’s governing institutional review board/ethics commit-
tee, reﬂecting national requirements for study conduct approval.
All patients provided written informed consent.
In these phase 3, multicenter, placebo-controlled trials,
patients were randomly assigned (1:1:1) to receive ustekinumab
45 mg, 90 mg, or placebo, at wk 0, wk 4 and every 12 wks
(q12wks) thereafter. Randomisation was stratiﬁed by investiga-
tional site, baseline weight (≤/>100 kg), and baseline metho-
trexate (MTX) usage (yes/no). At wk 16, patients with <5%
improvement from baseline in tender and swollen joint counts
entered blinded early escape; patients receiving placebo
switched to ustekinumab 45 mg, those receiving ustekinumab
45 mg increased to 90 mg, and patients receiving ustekinumab
90 mg continued with their blinded dose regimen. Placebo
patients who did not early escape crossed over to receive usteki-
numab 45 mg at wk 24, wk 28 and q12wks thereafter.
Radiographic assessments
Radiographic evaluations of the hands and feet were performed at
baseline, wk 24 and wk 52 regardless of early escape status, or at
the time of study drug discontinuation (unless radiographs were
obtained within the prior 8 wks). Centrally digitised images for
each patient at all three time points within each trial were scored
at the same reading session by two independent readers (and by an
adjudicator if the absolute difference of the change from baseline
in total vdH-S score between the two readers was >10 or if the
change from baseline in total score was missing for one reader), in
a random order and without knowledge of time point, patient
identity, or treatment assignment; scoring occurred continuously
from June 2011 to November 2012 within the clinical pro-
grammes. The images were scored using the PsA-modiﬁed vdH-S
method.10 To assess PsA-speciﬁc radiological damage, scores for
the distal interphalangeal hand joints and pencil-in-cup/gross oste-
olysis deformities were added to the original vdH-S score.11 The
total PsA-modiﬁed radiographic score ranges from 0 to 528 (total
score is sum of erosion score (0–320) and joint space narrowing
(JSN) score (0–208)). Higher scores and more positive score
changes indicate more existing radiographic damage and more
radiographic progression, respectively.
Statistical analysis
Progression of structural damage was measured by change from
baseline in total PsA-modiﬁed vdH-S scores of the hands and feet
at wk 24. As prespeciﬁed, this major secondary study endpoint
was analysed based on an integrated data analysis combining data
from the PSUMMIT-1 and PSUMMIT-2 studies with all rando-
mised patients included. Patients were analysed according to ran-
domised treatment group, irrespective of early escape. Analysis
of variance on the van der Waerden normal scores, that is, rank-
transformed scores based on normal distribution,12 with treat-
ment, patients’ baseline MTX usage (yes/no), and study indicator
(PSUMMIT-1 or PSUMMIT-2) as factors in the model was
employed to test the treatment difference. To control for multi-
plicity, the initial analysis tested the difference between the com-
bined ustekinumab groups (45 mg and 90 mg combined) and the
placebo group. If this was signiﬁcant, then pairwise tests, using
integrated data from both studies, were to be performed for each
individual dose group versus the placebo group.
If the total PsA-modiﬁed vdH-S score was missing for a given
patient at any of the wk 0, wk 24, or wk 52 visits, missing data
were imputed. Two methods were used for imputation. If the
X-ray data were available at two time points during the period
from wk 0 to wk 24, or from wk 24 to wk 52, the total
PsA-modiﬁed vdH-S scores at these two time points were lin-
early extrapolated to the missing visit in the same period.
Alternatively, if radiographic data were insufﬁcient for linear
extrapolation, the median of the change in the total scores
based on all patients within the same MTX stratiﬁcation at the
missing visit was assigned. Please see online supplementary text
for a description of the sensitivity analyses performed.
Radiographic data were also analysed as a binary variable
based on observed data (no imputation of missing data), using
the following cut-points of change from baseline to wk 24 in
total vdH-S score for ‘nonprogressors,’ as deﬁned by (1) change
less than the smallest detectable change (SDC), which measures
the variability of the difference in the change score between two
readers, and can be viewed as the amount of change from base-
line for which any smaller change cannot be reliably distin-
guished from random error in the measurement13 and (2)
change ≤0.0. The Cochran–Mantel–Haenszel test adjusting for
baseline MTX use and individual studies was used to assess dif-
ferences between the active treatment and placebo groups. All
tests were two-sided at a signiﬁcance level of α=0.05, and radio-
graphic data from the individual studies were analysed in a
similar manner. Please see online supplemental text for details
of sample size estimation.
RESULTS
Patient disposition and baseline radiographic characteristics
Patient screening began in November 2009, and the wk 52 clin-
ical database locks occurred in July (PSUMMIT-1) and
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December (PSUMMIT-2) of 2012; the radiographic database
was locked in January 2013. Overall, 1771 patients were
screened for the PSUMMIT-1 and PSUMMIT-2 trials, of whom
927 patients (747 anti-TNF-naive, 180 anti-TNF-experienced)
were randomised to treatment. A majority of the anti-TNF-
experienced subgroup had been exposed to ≥2 anti-TNF agents
(55% of patients) and had previously demonstrated lack of
efﬁcacy or intolerance to anti-TNF-therapy (>70% of patients).
The trials were conducted at 189 sites in European (565
patients), North American (319 patients), and Asia-Paciﬁc (43
patients) countries. Patient disposition through 1 year has been
previously described for each trial.8 9
Missing data were imputed via linear extrapolation or assign-
ment of the median of change scores within the same MTX
stratiﬁcation. For the integrated dataset, the overall rates of
missing radiographic data at wk 24 were low in all groups (ie,
2.3–10.3%) and would not be expected to impact the interpret-
ability of the integrated analyses of the effect of ustekinumab on
structural damage. Across both studies, median imputation was
the predominant means of replacing missing data. However, the
PSUMMIT-1 and PSUMMIT-2 studies differed in terms of the
amount and pattern of missing radiographic data. The highest
rate of missing data was observed in the anti-TNF-experienced
population in the PSUMMIT-2 study, mainly resulting from
early (within initial 8 wks) study agent discontinuation, and was
more than twofold higher among placebo-treated than
ustekinumab-treated patients for anti-TNF-experienced (24.2%
vs 9.3%) and anti-TNF-naive (11.9% vs 5.6%) patients within
the PSUMMIT-2 study. The missing data rate was generally
lower and more consistent across treatment groups in the
PSUMMIT-1 study (table 1). In all dosing arms, the median
changes from baseline in total vdH-S scores and subscores were
zero (see table 2). Therefore, the calculations assumed no
change in radiographic progression for patients requiring
median imputation.
Baseline patient and disease characteristics for the individual
PSUMMIT-18 and PSUMMIT-29 trials have been reported in
detail. Within each study, approximately 50% of patients were
using concomitant MTX at baseline.8 9 Baseline vdH-S scores,
pooled across both studies, were comparable across the three
randomised treatment groups. Baseline median total vdH-S
scores were higher in PSUMMIT-1 than in PSUMMIT-2, largely
due to numerically lower scores in the PSUMMIT-2 anti-TNF-
experienced patients (see online supplementary table S1).
Table 1 Patients requiring missing data imputation* for change
from baseline in total PsA-modified vdH-S score at wk 24;
randomised patients in PSUMMIT-1 and PSUMMIT-2
Ustekinumab
Placebo (%) 45 mg (%) 90 mg (%)
Patients in PSUMMIT-1 +
PSUMMIT-2, n
310 308 309
Requiring median imputation 32 (10.3) 12 (3.9) 15 (4.9)
Requiring linear extrapolation 7 (2.3) 7 (2.3) 10 (3.2)
Patients in PSUMMIT-1, n 206 205 204
Requiring median imputation 12 (5.8) 6 (2.9) 5 (2.5)
Requiring linear extrapolation 3 (1.5) 5 (2.4) 5 (2.5)
Patients in PSUMMIT-2, n 104 103 105
Requiring median imputation 20 (19.2) 6 (5.8) 10 (9.5)
Requiring linear extrapolation 4 (3.8) 2 (1.9) 5 (4.8)
Anti-TNF naive patients, n 42 43 47
Requiring median imputation 5 (11.9) 2 (4.7) 3 (6.4)
Requiring linear extrapolation 1 (2.4) 0 2 (4.3)
Anti-TNF-experienced patients, n 62 60 58
Requiring median imputation 15 (24.2) 4 (6.7) 7 (12.1)
Requiring linear extrapolation 3 (4.8) 2 (3.3) 3 (5.2)
*Missing X-ray data were imputed via linear extrapolation if X-ray data were available
at two time points during the period from wk 0 to wk 24, or from wk 24 to wk 52
or, if radiographic data were insufficient for linear extrapolation, via assignment of
the median of the change in the total scores based on all patients within the same
MTX stratification at the missing visit.
anti-TNF, anti-tumour necrosis factor α; MTX, methotrexate; PsA, psoriatic arthritis;
vdH-S, van der Heijde-Sharp; wk, week.
Table 2 Summary of integrated analyses of change from baseline in total PsA-modified vdH-S score at wk 24; randomised patients
Ustekinumab
Placebo Combined 45 mg 90 mg
Integrated data analysis of change from baseline to wk 24 in total vdH-S
score in the PSUMMIT-1 and PSUMMIT-2 studies—Major 2° endpoint, n
310 617 308 309
Mean±SD 1.0±3.9 0.4±2.3 0.4±2.1 0.4±2.4
Median (IQ range) 0.0 (0.0, 1.0) 0.0 (0.0. 0.5) 0.0 (0.0, 0.5) 0.0 (0.0, 0.5)
p Value <0.001 0.017 <0.001
Integrated data analysis of patients with change in vdH-S score*, n 271 573 289 284
Change ≤ SDC (2.01), n (%) 227 (83.8) 526 (91.8) 265 (91.7) 261 (91.9)
p Value <0.001 0.005 0.004
Change ≤ 0.0, n (%) 162 (59.8) 381 (66.5) 185 (64.0) 196 (69.0)
p Value 0.061 0.317 0.026
Integrated data analysis of patients with pencil-in-cup or gross osteolytic
deformities among those with evaluations at baseline and wk 24*, n
271 575 291 284
Reader 1, n (%)
Baseline 7 (2.6) 22 (3.8) 13 (4.5) 9 (3.2)
Wk 24 8 (3.0) 22 (3.8) 13 (4.5) 9 (3.2)
Reader 2, n (%)
Baseline 9 (3.3) 15 (2.6) 11 (3.8) 4 (1.4)
Wk 24 9 (3.3) 17 (3.0) 11 (3.8) 6 (2.1)
*No missing data imputation rules were applied.
anti-TNF, anti-tumour necrosis factor α; PsA, psoriatic arthritis; SDC, smallest detectable change; vdH-S, van der Heijde-Sharp; wk, week.
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Primary radiographic analysis: integrated data analysis of
change from baseline to wk 24 in the total vdH-S score
(major secondary study endpoint)
The study achieved the prespeciﬁed major secondary endpoint,
that is, integrated analysis of change in the total modiﬁed vdH-S
score at wk 24, such that patients in both ustekinumab dose
groups demonstrated signiﬁcantly less radiographic progression
at wk 24 versus patients in the placebo group (table 2, ﬁgures 1
and 2). Results of all sensitivity analyses conducted (see online
supplementary text) support the robustness of these ﬁndings
(data not shown). Inhibition of radiographic progression was
observed for ustekinumab doses versus placebo, regardless of
concomitant MTX status at baseline. In the ∼75% of patients
weighing ≤100 kg, less radiographic progression was observed
in ustekinumab-treated than placebo-treated patients; no treat-
ment effect was observed in patients weighing >100 kg,
although the number of patients in this subgroup was smaller,
and the magnitude of radiographic progression was low in the
placebo group.
As shown in online supplementary table S2 and ﬁgure 2, dis-
crete study results indicated that the treatment effect observed
in the integrated data analysis was derived from the
PSUMMIT-1 study (615 anti-TNF-naive patients), while no
clear treatment effect was observed in the smaller PSUMMIT-2
study (312 patients, including 122 anti-TNF-naive and 180
anti-TNF-experienced patients).
Integrated data analysis of additional radiographic
endpoints at wk 24
Non-progression of structural damage. At wk 24, signiﬁcantly
higher proportions of ustekinumab-treated (91.7%) than
placebo-treated (83.8%; p=0.005 vs combined ustekinumab)
patients demonstrated no radiographic progression, as deﬁned
by change in total PsA-modiﬁed vdH-S score from baseline
≤SDC (=2.01). Similar response patterns were observed when
patients were classiﬁed as ‘nonprogressors’ based on changes
from baseline to wk 24 ≤0.0, although statistical signiﬁcance
was reached only with the 90 mg dose (table 2).
Type of damage. Ustekinumab-treated patients demonstrated
signiﬁcantly less erosive progression than placebo-treated
patients (mean changes of 0.2 for 45 and 90 mg vs 0.6 for
placebo, p<0.01 for both comparisons). Numerically less JSN
was also observed at wk24 in the ustekinumab groups (mean
changes of 0.2 for 45 mg and 90 mg) than in the placebo group
(mean change of 0.4; p=not signiﬁcant), and consistent results
were observed when change in vdH-S score at wk 24 was ana-
lysed for hands and feet separately (data not shown).
Pencil-in-cup and gross osteolysis deformities. The proportions
of patients with pencil-in-cup or gross osteolysis deformities
were low at baseline (2.6% to 3.8% of patients) and remained
stable at wk 24 (3.0% to 3.8%; table 2).
Integrated radiographic data analysis through wk 52
Inhibition of structural damage among ustekinumab-treated
patients was sustained beyond wk 24 and through wk 52.
Speciﬁcally, mean changes in total PsA-modiﬁed vdH-S scores
among patients initially randomised to either ustekinumab
45 mg or 90 mg were 0.2 and 0.3, respectively, from wk 24 to
wk 52, compared with mean changes of 0.4 (45 mg) and 0.4
(90 mg) from baseline to wk 24 (table 3, ﬁgure 1B). Consistent
with ustekinumab’s treatment effect, patients initially rando-
mised to placebo who began receiving ustekinumab 45 mg at
wk 16 or wk 24 exhibited a marked decrease in radiographic
progression from wk 24 to wk 52 (mean change: 0.1) when
compared with that from wk 0 to wk 24 (mean change: 1.1).
Of note, the difference in the progression of structural damage
between ustekinumab-randomised and placebo-randomised
patients persisted through wk 52.
Consistent with ﬁndings at wk 24, the proportions of patients
with pencil-in-cup or gross osteolysis deformities remained low
and stable at wk 52, that is, 9/239 (3.8%) placebo patients for
Figure 1 Changes in PsA-modiﬁed vdH-S score—mean change from baseline over time through week 52 (A) and cumulative probability plot of
change from baseline to week 24 (B). Pbo, placebo; PsA, psoriatic arthritis; SDC, smallest detectable change; UST, ustekinumab; vdH-S, van der
Heijde-Sharp.
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both readers and 19/509 (3.7%) and 13/509 (2.6%) combined
ustekinumab patients for readers 1 and 2, respectively.
DISCUSSION
Approximately two-thirds of PsA patients will experience pro-
gressive joint damage, which is often associated with functional
loss and disability.14 Although the time-course of radiographic
progression varies widely, within 2 years of PsA onset, 47% of
patients manifest ≥1 erosion and after ≥10 years of follow-up
55% develop ≥5 deformed joints.15
While research in rheumatoid arthritis (RA) has identiﬁed a
strong link between inﬂammation and subsequent joint damage,
the mechanism behind the structural joint damage in PsA is less
deﬁned. Recently, though, collective data from in vitro/in vivo
experiments point to the role of IL-23 and the Th17 pathway in
PsA’s bone erosion and dysregulated bone formation.
Speciﬁcally, osteoclast precursors (cells that differentiate into
osteoclasts via osteoclastogenesis) are elevated in the circulation
of PsA patients.16 Also, IL-17 can cause cartilage degradation
via effects on chondrocytes.17 IL-23, independent of Th17, also
plays a direct role in PsA pathology including enthesitis, a
prominent feature of PsA. Sherlock et al 18 demonstrated an
IL-23R+ entheseal resident lymphocyte cell population that is
activated by IL-23, that produces IL-22, and can promote
entheseal and periosteal bone formation.
Beyond these preclinical data, however, evidence for a role of
this pathway in PsA bone pathogenesis would ideally arise from
targeted inhibition of pathway components in clinical trials.
Herein we report that ustekinumab 45 and 90 mg afforded sig-
niﬁcant and sustained inhibition of radiographic progression in
patients with active PsA. This supports the roles of IL-23 and
the downstream Th17 pathway in the radiographic damage that
occurs in most PsA patients.
Within the limitations of cross-trial comparison, the radio-
graphic treatment effect of ustekinumab among anti-TNF-naive
patients in PSUMMIT-1 reported herein appears consistent with
those reported for anti-TNF agents in anti-TNF-naive patients
with PsA.19–22 This is particularly true when considering the
low progression rate among ustekinumab-treated anti-TNF-naive
patients in PSUMMIT-1, and when considering the progression
observed in placebo-treated patients as a frame of reference. It
will, however, be important to monitor the radiographic pro-
gression through 2 years of ustekinumab therapy in the
PSUMMIT-1 trial to conﬁrm these ﬁndings. The observation of
Figure 2 Changes in PsA-modiﬁed vdH-S score from baseline to week
24 for the combined PSUMMIT-1 and 2 ((A)—primary analysis),
PSUMMIT-1 (B), and PSUMMIT-2 (C) trials. PsA, psoriatic arthritis; UST,
ustekinumab; vdH-S, van der Heijde-Sharp.
Table 3 Summary of change in total PsA-modified vdH-S score
from wk 0 to wk 24, wk 24 to wk 52, and wk 0 to wk 52;
integrated data analysis of randomised patients in the PSUMMIT-1
and PSUMMIT-2 studies
Treatment group Wk 0–24 Wk 24–52 Wk 0–52
Placebo → 45 mg*, n 269 269 269
Mean±SD 1.1±4.1 0.1±2.1 1.2±5.4
Ustekinumab 45 mg, n 308 308 308
Mean±SD 0.4±2.1 0.2±1.8 0.6±2.6
Ustekinumab 45 mg only‡, n 252 252
Mean±SD 0.3±2.0 0.1±1.8
Early escape (45 mg→90 mg)†, n 56 56
Mean±SD 0.8±2.4 0.4±2.2
Ustekinumab 90 mg, n 309 309 309
Mean±SD 0.4±2.4 0.3±2.1 0.7±3.7
Ustekinumab 90 mg only‡, n 261 261
Mean±SD 0.2±1.5 0.2±1.6
Early escape (90 mg→90 mg)†, n 48 48
Mean±SD 1.6±4.9 0.5±3.7
*Patients who did not receive ustekinumab are excluded.
†Patients who met early escape criteria at wk 16.
‡Patients who did not meet early escape criteria at wk 16.
PsA, psoriatic arthritis; vdH-S, van der Heijde-Sharp; wk, week.
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less progression of structural damage in obese patients has been
reported in RA patients, although the mechanistic basis of this
observation has not been determined.23 24
Analysis of individual study results indicated the treatment
effect observed in the predeﬁned integrated PSUMMIT-1 and
PSUMMIT-2 analyses was derived from the PSUMMIT-1 study
(see online supplementary table S2). While differences in treat-
ment effect between the two studies may derive from the
smaller size and heterogeneity of the PSUMMIT-2 population,
the two studies also differed in terms of missing data. The
highest rate was observed in anti-TNF-experienced, placebo-
treated patients within the PSUMMIT-2 study that included sub-
stantial numbers of anti-TNF-refractory patients, which then
translated into higher rates of mandated data extrapolation. The
higher rate of missing data in PSUMMIT-2 (table 1) was mainly
a result of early (within the ﬁrst 8 wks) discontinuations from
the trial, with the majority occurring in the placebo arm. Per
protocol, such patients did not qualify for radiographs upon dis-
continuation due to concerns related to excessive short-term
radiation exposure. By contrast, the rate of missing data was
generally low and consistent across the treatment groups in
PSUMMIT-1 (table 1). Thus, the application of data-handling
rules impacted PSUMMIT-2 more than PSUMMIT-1.
Speciﬁcally, since most missing data required median imput-
ation, the prespeciﬁed median imputation rules can be consid-
ered to have conservatively favoured the placebo group due to a
higher proportion of placebo patients having a score of 0
applied to missing data. Although the treatment effect was not
demonstrated in the anti-TNF-naive population in PSUMMIT-2
(unlike PSUMMIT-1), comparison of radiographic ﬁndings
between these two trial populations is limited by the low pro-
gression rate seen across all randomised groups (including
placebo) of the PSUMMIT-2 trial relative to placebo-treated
patients in PSUMMIT-1.
Thus, ustekinumab 45 mg and 90 mg through 1 year afforded
signiﬁcant and sustained inhibition of radiographic progression
in active PsA, supporting the role of IL-23 and the Th17
pathway in the radiographic damage of PsA. This is the ﬁrst
alternate mechanism of action for which the effect on PsA
radiographic progression has been established, following
anti-TNF agents. The PSUMMIT-1 trial continues through
2 years, and radiographic progression through 2 years of usteki-
numab therapy will be assessed. The effect of ustekinumab on
progression of structural damage in anti-TNF-experienced
patients has not been established, although it also has not been
adequately studied.
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